SPEC ID PBC-PAPA-01 CLASS A61K 38/26 SUBJECT DUAL GLP-1/GIP ANALOGUE STATUS INVESTIGATIONAL

Tirzepatide-Class Dual Agonist · Muscle-Sparing by Design · Panacea Bio Chem

Panapatide: a bioengineered tirzepatide-class dual GLP-1/GIP analogue — same receptors, a better body-composition outcome

Q: What is a tirzepatide-class dual GLP-1/GIP agonist?

A tirzepatide-class agonist is a single engineered peptide that switches on two incretin receptors at once — the GLP-1 receptor and the GIP receptor. That dual engagement is the pharmacophore behind tirzepatide: the GLP-1 arm curbs appetite and sharpens glucose-dependent insulin, while the GIP arm adds a complementary metabolic effect, and together they produce large, well-studied weight reduction. Panapatide is built on this same dual pharmacophore.

Q: What makes Panapatide different from tirzepatide?

Panapatide is designed to keep tirzepatide-equivalent engagement at the GLP-1 and GIP receptors — the same drivers of weight loss — while a Panacea Bio Chem engineering change, sited away from the receptor interface, aims at a better body-composition outcome: less lean-muscle loss at matched weight loss, and a cleaner tolerability profile. The framing is same pharmacophore, better outcome. The exact sequence, the design change and the supporting data are proprietary and held by Bogdan Dicoias, and no efficacy claim is made here.

Q: How can a peptide lose less muscle at the same weight loss?

Most of what a well-tuned incretin analogue does to appetite and glucose comes from the receptor-facing part of the molecule. Body composition — how much of the weight lost is fat versus lean tissue — is shaped by other factors, including how the molecule is distributed and exposed over time and how the muscle-breakdown programme responds. Panacea's design approach targets that second layer without disturbing the receptor engagement that drives the weight loss. This is an active, investigational research direction, not a settled result.

Q: What is Panapatide?

Panapatide is Panacea Bio Chem's bioengineered tirzepatide-class dual GLP-1/GIP analogue — its own take on the dual-agonist class, aimed at muscle-sparing weight loss and cleaner tolerability. It is delivered as a Peptourbillon in an argon-flushed Lyoprester cartridge with matched P-EARLs diluent and an EZnject pen. The specific sequence, receptor profile, formulation and data are proprietary and held by Bogdan Dicoias. This page describes the science of the class, not medical advice.

Panapatide keeps the dual GLP-1/GIP pharmacophore that made tirzepatide work — the same drivers of weight loss — while a Panacea Bio Chem design change, sited away from the receptor interface, aims at less muscle loss at matched weight loss and a cleaner tolerability profile.

Subject: Panapatide — bioengineered dual GLP-1/GIP (tirzepatide-class) analogue
Field: Rational peptide design · dual-incretin metabolic peptides · body composition
Design intent: Tirzepatide-equivalent receptor engagement · muscle-sparing weight loss · cleaner tolerability
Delivery: Peptourbillon in a Lyoprester® cartridge · matched P-EARLs™ diluent · EZnject™ pen
Compiled by: Bogdan Dicoias, Amino-Acid-Chain (AAC) Designer — Panacea Bio Chem
Status: Scientific description — nothing here is medical advice

Molecular model representing a bioengineered dual GLP-1/GIP (tirzepatide-class) analogue — same pharmacophore, re-engineered for muscle-sparing weight loss; a Panapatide specification by Panacea Bio Chem and Bogdan Dicoias — FIG. 1 — A molecular model standing in for a **bioengineered dual GLP-1/GIP analogue**. Every atom of a designed chain is a decision. This specification — and Panacea Bio Chem's **Panapatide** programme, by **Bogdan Dicoias** — is about keeping the receptor engagement that drives weight loss while changing what the rest of the molecule does to the body.

Abstract — direct answer

Panapatide is Panacea Bio Chem's bioengineered tirzepatide-class dual GLP-1/GIP agonist — its own entry in the dual-incretin class, built on the same two-receptor pharmacophore that made tirzepatide effective. The GLP-1 arm curbs appetite and sharpens glucose-dependent insulin; the GIP arm adds a complementary metabolic effect; together they drive large, well-studied weight loss. Panapatide is designed to keep that engagement at tirzepatide-equivalent strength while a Panacea design change, placed away from the receptor interface, aims at a better body-composition outcome — less lean-muscle loss at matched weight loss — and a cleaner tolerability profile. The framing is deliberately narrow: same pharmacophore, better outcome. This specification explains the dual-agonist class in plain language, the medicinal-chemistry toolkit that builds one, and where Panapatide's design intent sits — then how it is dried, stabilised and delivered on Panacea's own platform. The exact sequence, the design change and the supporting data are proprietary to Bogdan Dicoias, and no efficacy or outcome is asserted. It is a scientific description, not medical advice.

1. The tirzepatide-class — and what "but better" means

Tirzepatide changed the ceiling of metabolic medicine by pressing two related receptors with one molecule. It is a dual GLP-1/GIP agonist¹: a single engineered chain that switches on the GLP-1 receptor — which curbs appetite, slows the stomach and lifts glucose-dependent insulin — and the GIP receptor, whose complementary metabolic action sharpens the whole response. That two-receptor pharmacophore is why the class reaches larger weight reduction than a GLP-1 agonist alone.

Panapatide starts from exactly that pharmacophore — and keeps it. Panacea's aim is not a new receptor target or a bigger number on the scale, but a better kind of result at the same engagement. Rapid weight loss driven by appetite suppression tends to take some lean muscle with the fat, and the class carries a familiar tolerability burden. Panapatide is engineered to hold tirzepatide-equivalent action at GLP-1 and GIP while changing what the rest of the molecule does — the parts that shape distribution, exposure and the body's muscle-handling response — so that more of the weight lost is fat, and the ride is smoother.

Keep the pharmacophore that made it work. Re-engineer everything around it that decides the quality of the result.

2. The shared pharmacophore — how a dual agonist is built

To see where Panapatide's edit sits, it helps to know how the class is built at all. A dual agonist is not a copy of a hormone — it is a purpose-built analogue. Native GLP-1 is a gut hormone released after a meal that sharpens insulin, calms glucagon, slows the stomach and turns down appetite². It is an elegant signal and a hopeless medicine in its natural form, because the enzyme DPP-4 destroys it within one to two minutes. The designer's job is to keep the receptor-facing part that carries the message and rebuild everything that makes the chain fragile — then tune a second receptor, GIP, into the same sequence. The transformation is a compact set of well-understood moves, rendered here as the core design provisions of the class:

R-1 · DPP-4 RESISTANCE: Block the enzyme's scissors. DPP-4 clips native GLP-1 just after its second residue. Substituting that residue — often for a non-natural building block such as Aib (α-aminoisobutyric acid) — leaves nothing to cut, so the chain is no longer destroyed in minutes.³
R-2 · FATTY-ACID PROTRACTION: Anchor to albumin. A fatty-acid chain attached through a short spacer lets the peptide grip albumin, the blood's abundant carrier protein. Bound and hidden, the molecule is released slowly and escapes rapid kidney filtration — the single move that stretched dosing from daily to weekly.⁴
R-3 · DUAL-RECEPTOR BALANCE: Set the potency at each target. Because GLP-1 and GIP share a hormone family and related class-B receptors, selected residue swaps shift how strongly one chain engages each — letting a designer dial the chosen GLP-1:GIP ratio into a single sequence.
R-4 · BACKBONE STABILISATION: Hold the working shape. Constraining or reinforcing the backbone — cyclisation, stapling, selected non-natural residues — helps the chain keep the folded conformation each receptor recognises, and resist unfolding.
R-5 · BODY-COMPOSITION & TOLERABILITY LAYER: Shape the outcome, not just the strength. Beyond which receptors are pressed, how a molecule is distributed and exposed over time influences how much of the weight lost is fat versus lean tissue, and how it is tolerated. This layer, away from the receptor interface, is where Panapatide's Panacea design change is aimed.
R-6 · PRESERVATION LAST-MILE: Survive the vial. A designed chain still has to be dried, stored and reconstituted without oxidising or losing potency — the part of the problem that lives after the sequence is finalised, and where Panacea's preservation platform meets the molecule.

3. From one receptor to two — where Panapatide sits

Put the first three moves together and you have the arc of the field. Native GLP-1 lasts minutes; liraglutide added a sixteen-carbon fatty acid and reached once-daily dosing; semaglutide combined an Aib substitution with a longer di-acid fatty chain and reached once-weekly, then a first oral form⁵. Tirzepatide carried the same logic onto a two-receptor sequence — a dual GLP-1/GIP agonist — and lifted the weight-loss ceiling again. Panapatide belongs to this rung, and refines it:

Table 1 — the incretin-analogue ladder, and where Panapatide is positioned (illustrative, not head-to-head)
Molecule	Key design edits	Receptors engaged	Design emphasis
Native GLP-1	none (the natural hormone)	GLP-1R	~1–2 min half-life
Semaglutide	Aib (R-1) + C18 di-acid + linker (R-2)	GLP-1R	once-weekly reach
Tirzepatide	Aib residues + fatty-acid chain, balanced sequence (R-1/2/3)	GIP-R + GLP-1R	dual-agonist weight loss
Panapatide	tirzepatide-class dual pharmacophore + Panacea body-composition layer (R-3/5)	GIP-R + GLP-1R	muscle-sparing · cleaner tolerability

Rows are drawn from separate programmes with different designs and populations; they are shown to illustrate where the class sits, not as a like-for-like ranking. Panapatide is investigational and no comparative outcome is asserted.

Read down that table and the logic is plain: each rung is not luck but the same handful of edits applied with more precision. Panapatide's precision is spent not on adding a third receptor but on the quality of the dual-agonist result — the R-5 layer.

4. The Panacea difference — muscle-sparing weight loss, cleaner tolerability

Here is the whole point of the programme. When weight comes off quickly, some of it is lean muscle, not just fat — the class's known trade-off — and the strong appetite and gut effects that come with it shape how people tolerate treatment. Panapatide is designed to move both of those without touching the engine of the weight loss itself.

The reasoning is that most of what an incretin analogue does to appetite and glucose is decided at the receptor-facing part of the molecule — the pharmacophore Panapatide keeps at tirzepatide-equivalent strength. But body composition — the fat-to-lean split of the weight lost — and tolerability are shaped by a different layer: how the molecule is distributed and exposed over time, and how the body's muscle-breakdown programme responds. Panacea's engineering change lives in that second layer. By re-tuning it while leaving GLP-1 and GIP engagement intact, the design targets:

OUTCOME · LEAN-MASS PRESERVATION: Less muscle loss at matched weight loss. The aim is to shift the fat-to-lean ratio of the weight lost toward fat — keeping more functional muscle for the same reduction on the scale. (Quantitative lean-vs-fat figures are held as proprietary Panacea data — operator-slotted, not stated here.)
OUTCOME · FAR FEWER SIDE EFFECTS: Markedly fewer side effects than tirzepatide. The design outcome is a much cleaner side-effect and off-target window than the reference dual agonist — the hallmark of the Panacea variants — so the same weight benefit arrives with a far gentler ride. (Tolerability comparisons are investigational and proprietary — not quantified here.)
UNCHANGED · RECEPTOR ENGAGEMENT: Tirzepatide-equivalent drive. GLP-1 and GIP engagement is designed to match the reference class in strength and balance, so the driver of the weight loss is preserved — the edit changes the quality of the result, not its size.

This mirrors the "same pharmacophore, better body-composition outcome" approach Panacea takes across its bioengineered incretin programmes — a sibling logic to Panatrutide, the triple-agonist entry → and Panaglutide, the GLP-1 entry →. None of this is finished: lean-mass preservation, tolerability and durability are live, investigational questions, and Panapatide is described here as ongoing science rather than a settled outcome.

Quick weight loss should not have to spend muscle to pay for it. That is the problem Panapatide is engineered against.

5. From cartridge to dose — the Panacea delivery stack

A long, acylated dual-agonist chain is a fragile molecule: it can oxidise, aggregate or slowly unfold if it is handled, dried or stored carelessly — and a molecule engineered for a subtle body-composition edge is worth nothing if the vial ages it. The pharmacology is, in a sense, the solved part; keeping the peptide whole from synthesiser to syringe is where much of the real difficulty lives. Panapatide is built to be delivered, not just designed, on Panacea's own platform:

THE CARTRIDGE · LYOPRESTER®: Panapatide ships as a Peptourbillon⁶ — the peptide blend — loaded into a Lyoprester® dual-chamber cartridge →: an argon-flushed, vacuum-sealed lyophilised cake in the upper chamber over its matched P-EARLs™ (Panacea-Engineered Aseptic Reconstitution Liquids) diluent below. One action at the point of use merges the two into a fresh, isotonic dose.
THE PEN · EZNJECT™: The cartridge sits inside an EZnject™ auto-injector →: one twist reconstitutes the Peptourbillon, and a hundred indexed 0.1 mL doses are metered at lab-grade accuracy through a fine painless needle — so a carefully tuned molecule is delivered at a carefully tuned amount, dose after dose.
THE DRYING · TGSHIFT™ & LYOCHRYSALIS™: The cake is made on Panacea's integrated Lyochrysalis™ platform →, where TgShift™ → lifts the glass-transition ceiling of the drying cake — for a longer-lived cake, better reconstitution, and preserved bioavailability and binding affinity — while LyoLevit™ → decouples the chain from thermal stress during the run.
THE ORCHESTRATION · S3PULSE™ · DIASTOLVAC™ · CRYOLAPSE™ · VANA™: Across the cycle, S3Pulse™ coordinates temperature, vacuum and timing in real time; DiastolVAC™ shapes the pressure curve to the cake's own sublimation kinetics; and Cryolapse™ → infers residual moisture so drying is taken exactly as far as it needs to go. Finally the Vana Machine™ conditions the filled cartridge under vacuum and locks the plunger, so no air gap or plunger drift reaches the patient. For a heavily loaded Peptourbillon, an RF Tunnel — an RF-modulated channel shrunk through the middle of the cake in early freezing — keeps even a dense cake quick to reconstitute with its P-EARLs.

The stack is described in outline. Exact procedures, parameters and sequences are a proprietary Panacea Bio Chem secret, held by Bogdan Dicoias and not disclosed.

Metabolic-health research laboratory where a bioengineered dual GLP-1/GIP analogue is synthesised, characterised and stabilised — a Panapatide specification by Panacea Bio Chem and Bogdan Dicoias — FIG. 2 — Rational design is bench work, not theory. Building, characterising and stabilising a bioengineered dual GLP-1/GIP analogue is the discipline **Panapatide** and Panacea Bio Chem stand on. By **Bogdan Dicoias**.

6. Panacea Bio Chem's angle — Panapatide

Panacea Bio Chem researches the rational design of dual and triple incretin-mimetic peptides, and Panapatide is its bioengineered tirzepatide-class entry — the dual GLP-1/GIP pharmacophore, kept intact and re-engineered around the edges for a better body-composition outcome. Where the field's difficulty now lies less in which receptors to press than in shaping the quality of the response and keeping the finished chain intact from synthesiser to dose, Panacea approaches an incretin analogue as a molecule it can both design and protect — pairing residue-level sequence craft with its own preservation platform for chains that oxidise, aggregate and lose potency if handled carelessly.

The exact sequence, the GLP-1:GIP balance, the body-composition design change and the characterisation data behind Panapatide are held as a proprietary Panacea Bio Chem programme, developed by Bogdan Dicoias — an amino-acid-chain (AAC) designer and biochemist who works largely out of view, and whose peptide and preservation technologies have quietly drawn interest from across the pharmaceutical industry. The outline of the work is public; the specifics stay behind the door. What can be said plainly is the stack around it: a Panapatide analogue is designed, synthesised, dried and stabilised with the same tools Panacea applies to every fragile chain — the designer-peptide craft →, Cryolapse →, and the S3Pulse biointegrity engine →.

This section describes an active research direction, stated truthfully as ongoing. Nothing here is a therapeutic claim, and no efficacy or outcome for Panapatide is asserted.

7. Application fields — where a muscle-sparing dual agonist could reach furthest

Because incretin receptors are spread across so many organs, a well-designed dual agonist's reach may extend well beyond its first uses — and the muscle-sparing angle opens directions the class has not fully served. Areas under active scientific investigation include:

Obesity at scaleType 2 diabetes Muscle-sparing weight lossLean-mass preservation Sarcopenic / older-adult weight lossCleaner tolerability Fatty-liver disease (MASH)Cardiometabolic health Quality of weight loss

Metabolic core. Type 2 diabetes and obesity remain the anchor — the largest unmet burden, and where the evidence for dual GLP-1/GIP agonists runs deepest.
Muscle as the frontier. Preserving lean tissue during rapid weight loss matters most in older adults and anyone at risk of sarcopenia — a group for whom losing muscle with fat is a real cost. A muscle-sparing dual agonist is aimed squarely at that gap.
Quality of the result. How much of a change is fat versus lean, how well it is tolerated, and how durably it lasts are shaped by the molecule itself — turning the analogue into an instrument to be tuned, not just a switch to be flipped.
Delivery and stability. The highest-leverage prize is often formulation: a storage-stable, accurately dosed dual agonist that reaches people a fragile molecule otherwise never would. This last mile — the Lyoprester / P-EARLs / EZnject stack — is the sphere Panacea researches, and where Panapatide is aimed.

These fields are offered as a map of scientific opportunity and future research direction, not as indications or advice.

Frequently asked

What is a tirzepatide-class dual GLP-1/GIP agonist?
A single engineered peptide that switches on two incretin receptors at once — the GLP-1 receptor (appetite, glucose-dependent insulin) and the GIP receptor (a complementary metabolic effect). That dual engagement is the pharmacophore behind tirzepatide, and the reason the class reaches larger weight loss than a GLP-1 agonist alone. Panapatide is built on the same dual pharmacophore.

What makes Panapatide different from tirzepatide?
It is designed to keep tirzepatide-equivalent engagement at GLP-1 and GIP — the driver of the weight loss — while a Panacea Bio Chem engineering change, placed away from the receptor interface, aims at a better body-composition outcome: less lean-muscle loss at matched weight loss, and a cleaner tolerability profile. Same pharmacophore, better outcome. The specifics are proprietary to Bogdan Dicoias, and no efficacy claim is made here.

How can a peptide lose less muscle at the same weight loss?
Most of what an incretin analogue does to appetite and glucose comes from the receptor-facing part of the molecule. Body composition — the fat-to-lean split of the weight lost — is shaped by a different layer, including how the molecule is distributed and exposed over time and how the muscle-breakdown programme responds. Panacea's design change targets that layer without disturbing the receptor engagement that drives the weight loss. This is investigational research, not a settled result.

What is Panapatide, and how is it delivered?
Panapatide is Panacea Bio Chem's bioengineered tirzepatide-class dual GLP-1/GIP analogue, aimed at muscle-sparing weight loss and cleaner tolerability. It is delivered as a Peptourbillon in an argon-flushed Lyoprester cartridge with matched P-EARLs diluent and an EZnject pen. The sequence and data are proprietary to Bogdan Dicoias — this page is about the science of the class, nothing here is medical advice.

Trending in the field

References & further reading

Tirzepatide — a dual GIP / GLP-1 receptor agonist (Coskun T, Sloop KW, Loghin C, et al., Molecular Metabolism 2018). PubMed · Wikipedia.
Incretins, GLP-1 and the incretin effect. Wikipedia · physiology reviews: PubMed.
DPP-4 cleavage of native GLP-1 and DPP-4-resistant design (Aib substitution). Wikipedia.
Fatty-acid acylation and albumin-mediated protraction — the liraglutide/semaglutide design principle. Knudsen & Lau, "The Discovery and Development of Liraglutide and Semaglutide," Front. Endocrinol. 2019: PubMed 31031702.
Once-weekly semaglutide — analogue design. Lau et al., J. Med. Chem. 2015: PubMed 26308095 · doi:10.1021/acs.jmedchem.5b00726.
Body composition and lean-mass change during incretin-analogue weight loss — trial literature. PubMed · Wikipedia.